Adicet Bio receives FDA Fast Track Designation for ADI-270 in advanced kidney cancer

Adicet Bio, Inc.

ADI-270 granted Fast Track Designation for metastatic/advanced clear cell RCC after checkpoint and VEGF inhibitor therapy.
This is Adicet's first gamma delta 1 CAR T cell therapy candidate to enter clinical trials for solid tumors.
ccRCC is the most common type of kidney cancer; Fast Track aims to expedite development and review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.